Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: To D or not to D: That is the question

Ranjani Moorthi, Praveen Kandula, Sharon Moe

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose of review Patients with chronic kidney disease (CKD) are often insufficient in 25(OH) vitamin D and are almost uniformly deficient in 1,25(OH)2 vitamin D, because of decreased renal hydroxylation resulting from hyperphosphatemia and elevated fibroblast growth factor- 23 (FGF-23) levels. These same abnormalities lead to secondary hyperparathyroidism for which the administration of ca\lcitriol or vitamin D analogs has been the mainstay of therapy for decades. This review summarizes new trials of vitamin D, calcitriol, and its analogs over the last 2 years. Recent findings In addition to the endocrine effects of the vitamin D axis on bone and mineral metabolism, studies have demonstrated there is also extrarenal conversion of 25(OH) vitamin D to 1,25(OH)2 vitamin D in multiple cells leading to autocrine effects. This advance has led to the speculation that CKD patients may also need to be supplemented with ergocalciferol or cholecalciferol. Unfortunately, to date, the majority of interventional studies have focused on biochemical end points. There are no randomized controlled trials demonstrating that therapy with any formulation of vitamin D results in improved patient level outcomes. Summary Despite the physiologic importance of vitamin D in health and disease, more research is required to determine which vitamin D derivative is required for optimal health in CKD patients.

Original languageEnglish
Pages (from-to)354-359
Number of pages6
JournalCurrent Opinion in Nephrology and Hypertension
Volume20
Issue number4
DOIs
StatePublished - Jul 2011

Fingerprint

Calcitriol
Chronic Renal Insufficiency
Vitamin D
Ergocalciferols
Hyperphosphatemia
Secondary Hyperparathyroidism
Cholecalciferol
Health
Hydroxylation
Minerals
Randomized Controlled Trials
Kidney
Bone and Bones
Therapeutics
Research

Keywords

  • kidney
  • trials
  • vitamin D

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

@article{f73b5f16197749d88254843986d33137,
title = "Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: To D or not to D: That is the question",
abstract = "Lippincott Williams & Wilkins.",
keywords = "kidney, trials, vitamin D",
author = "Ranjani Moorthi and Praveen Kandula and Sharon Moe",
year = "2011",
month = "7",
doi = "10.1097/MNH.0b013e3283470450",
language = "English",
volume = "20",
pages = "354--359",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease

T2 - To D or not to D: That is the question

AU - Moorthi, Ranjani

AU - Kandula, Praveen

AU - Moe, Sharon

PY - 2011/7

Y1 - 2011/7

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - kidney

KW - trials

KW - vitamin D

UR - http://www.scopus.com/inward/record.url?scp=79958833543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958833543&partnerID=8YFLogxK

U2 - 10.1097/MNH.0b013e3283470450

DO - 10.1097/MNH.0b013e3283470450

M3 - Article

C2 - 21654391

AN - SCOPUS:79958833543

VL - 20

SP - 354

EP - 359

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 4

ER -